All Blogs
May 24, 2022
PTC Therapeutics’ Gene Therapy Upstaza; Sanofi and Regeneron’s Dupixent; Bayer CAR-T Collaboration with Atara; FDA Accepts Biohaven’s Zavegepant; AbbVie Files FDA Approval for ABBV-951; Innoviva to Acquire Entasis; FDA Orphan Drug Designation to XMT-2056; FDA Approves Azacitidine for Juvenile Myelomonocytic Leukemia
EU Recommends Approval for PTC Therapeutics’ Gene Therapy Upstaza Upstaza, a gene therapy developed by PTC Therapeutics for patients with the genetic condition AADC deficiency, has been recommended for EU approval, putting another test of gene therapy's commercial prospects in the union. Upstaza (eladocagene exu...
Read More...
May 23, 2022
Evaluation of the Advancing Developmental and Epileptic Encephalopathy Treatment Pipeline
Developmental and Epileptic Encephalopathy (DEE) refers to a group of severe epilepsies that are characterized both by seizures, which are often drug-resistant, as well as encephalopathy, which is a term used to describe significant developmental delay or even loss of developmental skills. In Developmental and Epil...
Read More...
Jun 19, 2026
Interpreting the Growth and Major Developments in the Medical Device Contract Manufacturing Market
Medical device contract manufacturing has evolved into one of the most dynamic and strategically critical segments of the global healthcare supply chain. As original equipment manufacturers (OEMs) and innovators face mounting pressure to accelerate time-to-market, reduce capital expenditure, and navigate an increas...
Read More...
May 19, 2022
Check-Cap’s Pivotal Trial for C-Scan; Curebase and Flow Neuroscience’s tDCS Device; Brainlab Acquires Majority Share in medPhoton; GE Healthcare to Invest in Pulsenmore; Medtronic’s Drug-Eluting Coronary Stent System; Remedee’ Endorphin Stimulation Solution;
Check-Cap Initiated the US Pivotal Trial for C-Scan® On May 11, 2022, Check-Cap Ltd., a clinical-stage diagnostic company initiated the US pivotal trial for C-Scan® at Mayo Clinic in Rochester Minnesota. C-Scan is the first and only patient-friendly, preparation-free screening test to detect polyps before they m...
Read More...
May 18, 2022
Evaluating the Major Developments in the Smart Pills Market
As our medical demands rise, so does the technology that distributes our medications. With innovative phone apps, alarms, smart packaging, and smart pills, there is no excuse to miss a dosage or forget to take your medication. With the evolution of wireless devices and microscopic cameras, the terms "embeddable" an...
Read More...
May 17, 2022
BMS Sells NY Biologics Plant; FDA Approves Mitsubishi Tanabe’s Radicava, Love Pharma Acquires MicroDoz; Sandoz Launches Generic of Roche’s Esbriet; Pfizer to Acquire Biohaven Pharma; eureKARE’s Cell and Gene Therapy CDMO; Atamyo’s LGMD Gene Therapies; FDA approves Eli Lilly’s Type 2 Diabetes Treatment
Love Pharma Completes the Acquisition of MicroDoz Therapy LOVE Pharma Co. has announced the completion of its acquisition of MicroDoz Theraphy Inc. ("MicroDoz"). Love Pharma holds exclusive manufacturing, marketing, packaging, selling, and distribution licenses in Europe, the United Kingdom, and North America. U...
Read More...
May 16, 2022
Discovering the Latest Developments in the Rapidly Advancing Abdominal Aortic Aneurysm Treatment Landscape
The heart is the most important muscle in the body. The aorta is the largest artery in the body and is the blood vessel that carries oxygen-rich blood away from the heart to all body parts. The section of the aorta that runs through the chest is called the thoracic aorta, and as the aorta moves down through the abd...
Read More...
May 13, 2022
Assessing How Emerging Therapies Will Transform the AL Amyloidosis Treatment Dynamics
AL Amyloidosis is a rare disease, with around 8,500 new cases diagnosed each year in the 7MM. This disease mostly affects elderly persons median age of 64, with slight male predominance (54%). As per our estimates, the highest AL Amyloidosis incidence was observed in the US in 2021. Moreover, there are more than 30...
Read More...
May 12, 2022
Abbott’s Alinity m STI Assay; Phillips’ MR 7700 System; HOYA’s MiYOSMART Spectacle Lens; Magneto’s Pulmonary Embolism Treatment; Owen Mumford and Stevanto Group’s Collaboration Deal; Elekta’s Radiosurgery System-Elekta Esprit
Abbott Receives Regulatory Approval from US FDA for Alinity™ m STI Assay On May 04, 2022, the US Food and Drug Administration (FDA) granted the regulatory approval to Alinity™ m STI Assay developed by Abbott which is capable of simultaneously detecting and differentiating four common sexually trans...
Read More...
Jun 06, 2025
Assessing the Growing Role & the Demand of Chronic Disease Management Apps
Over the past few years, the prevalence of chronic diseases has grown significantly, placing an increasing social and economic burden on individuals and families. Managing these long-lasting conditions requires constant attention to symptoms, medication, lifestyle changes, and emotional well-being. As a result, chr...
Read More...